H ypercholesterolemia is associated with an estimated 4.4 million deaths yearly and accounts for a considerable proportion of ischemic strokes and heart disease. 1 3 LDL-C levels therefore continue to constitute the primary targets of therapy. 4 Epidemiologic studies also predict that every 1% reduction in LDL-C decreases the risk of major cardiovascular events by 1% to 1.5%. 5, 6 Clinical evidence also points to the inverse relationship between high-density lipoprotein cholesterol (HDL-C) levels and the development of atherosclerosis. 7, 8 Since coronary artery disease (CAD) is the most common type of CVD, its primary as well as secondary prevention is of great importance. Patients with the highest baseline risk are most likely to benefit. 4, 9 Treatment goals depend on CVD risk stratification to identify appropriate lipid level 'targets' as recommended by the European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines. 10 Many lipid-lowering drugs have been developed, among which statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, were demonstrated in several clinical trials to be the best tolerated and most effective agents in decreasing serum cholesterol levels and reducing the risk of coronary events. [11] [12] [13] Rosuvastatin, a synthetic orally active agent, is considered the most potent statin to date.
14 It showed a dose-dependent LDL-C reduction of up to 65% and was found to be more effective than pravastatin and simvastatin in achieving LDL-C targets. 15 Another study compared rosuvastatin to the atorvastatin over 52 weeks, where the former produced greater reductions in LDL-C at the same dose in patients with primary hypercholesterolemia. 16 In Lebanon, CVD accounts for 45% of deaths.
17
While CVD risk can be reduced by statin therapy, 7, 18, 19 the clinical outcome of statin therapy among Lebanese, in line with the high CVD prevalence, is not fully assessed. The Dyslipidemia International Study (DYSIS) for Jordan and Lebanon showed that more than 70% of statin-treated patients in these countries were at very high risk for cardiovascular complications. The most frequent lipid abnormality in these patients, despite chronic statin treatment, was elevated LDL-C levels. Target LDL-C levels were not reached in 67% of very high risk patients. 20 Superstat (Resova in Saudi Arabia), a generic form of rosuvastatin manufactured by Hikma Pharmaceuticals, was launched in several countries including Saudi Arabia, Lebanon, Egypt, and Tunisia between 2010 and 2013. Superstat was determined to be bioequivalent to Crestor in a two-way, open-label, randomized, crossover study (Unpublished. Conducted by International Pharmaceutical Research Center, Amman, Jordan). The study investigated the bioequivalence of Hikma pharmaceuticals' generic rosuvastatin (20 mg rosuvastatin as calcium salt per film-coated tablet) relative to Crestor (AstraZeneca UK Limited; 20 mg rosuvastatin as calcium salt per film-coated tablet) after an oral single dose administration of 20 mg to healthy adults under fasting conditions. Thirty-two subjects completed the crossover; a one-week washout period was allowed between doses. Blood samples were collected over 72 hours and the rate and extent of absorption were analyzed based on the level of drug in human plasma, determined using liquid chromatography tandem mass spectrometry method. Both treatments were well tolerated. The two formulations (test and reference drugs) were found to have comparable 90% confidence intervals for different pharmacokinetic parameters (mean total area under the curve and maximum concentration were within the 80-125% accepted limit) and were thus considered bioequivalent.
To date, no published studies have been conducted to assess the efficacy and safety of rosuvastatin generics in a real-life setting, which is necessary to support their use for the control of hypercholesterolemia, and to reduce healthcare expenditures per patient. The objective of this study was to assess the safety and efficacy of a generic formulation of rosuvastatin in reducing plasma LDL-C in Lebanese dyslipidemic patients for both primary and secondary prevention of CVD based on total cardiovascular risk.
PATIENTS AND METHODS
This was an observational, non-comparative multicenter prospective clinical study to analyze data on the use of a generic formulation of rosuvastatin in hypercholesterolemic Lebanese adult outpatients. It included 24 cardiology, endocrinology, and general practitioner outpatient clinics; one investigator was assigned at each site. Generic rosuvastatin was prescribed at the treating physician's discretion, based on the current practice and medical indication, and independently from the recruitment into the study. Patients were followed at the clinic as per the standard practice of care for 2 months. The study protocol and informed consent were reviewed and approved by the institutional review boards of Al Rassoul Al Aazam and Hammoud Hospitals (Protocol for SPS-LBN-2014-05) before any study-related procedure took place. All patients recruited to the study gave written informed consent before any study related procedure took place or any study-related data was collected.
Data was collected from medical records and no visits or interventions outside the routine clinical practice were requested or performed. All patients prescribed generic rosuvastatin between 3 November 2014 and 3 August 2015 were screened for eligibility. Patients were included if they were ≥18 years old, had dyslipidemia requiring statin therapy according to CVD risk factors as per the ESC/EAS 2011 guidelines for primary or secondary prevention, and provided written informed consent. Patients were excluded if they had documented statin use in the past 3 months, had any contraindication to HMG-CoA reductase inhibitors, were taking a concomitant non-statin lipid lowering agent (ezetimibe, fibrates, niacin, or omega 3 fatty acids), had conditions that might cause secondary dyslipidemia, or had a blood triglyceride (TG) level of > 4.5 mmol/L (400 mg/dL), liver enzymes (aspartate transaminase (AST) or alanine transaminase [ALT]) ≥3 upper limit normal, or serum creatine kinase (CK) > 5 upper limit normal. Efficacy was based on the evaluation of the mean and percent change in LDL-C between baseline and week 8 after the initiation of therapy. Efficacy was also based on the evaluation of mean change in TG and HDL-C between baseline and week 8, as well as the proportion of patients reaching their target LDL-C levels at week 8 as defined by the treating physician at inclusion. Safety was based on the evaluation of the incidence of adverse events (AEs) during the study period in all eligible patients. AEs could include the worsening of baseline medical conditions, the occurrence of new conditions, or a significant change in vital signs or laboratory values. Efficacy and safety measurements were collected from medical records at baseline and at week 8 after initiation, when the first assessment was expected to occur. At baseline, data collected included medical and surgical history, patient demographics, height, weight, CVD risk factors, lipid profile tests (TG, LDL-C, HDL-C, total cholesterol), and concomitant medications use. The SCORE system was used to estimate the 10-year total cardiovascular risk for each patient based on two non-modifiable (age and gender) and 3 modifiable (systolic blood pressure, total cholesterol, and smoking status) risk factors. Accordingly, patients were categorized into four CVD risk levels: very high risk, high risk, moderate risk or low risk. 4 At the final visit (month 2), data collected included lipid profile tests (TG, LDL-C, HDL-C, total cholesterol), concomitant medications use, drug prescription, and AE recording.
The statistical analyses were performed using IBM SPSS Statistics for Windows, Version 22.0. (Armonk, NY: IBM Corp. Released 2013). The statistical analyses consisted of descriptive statistics for parameters of interest, statistical testing of the efficacy variables, and description of safety assessments. Data was described using means and standard deviations for continuous variables and proportions for categorical variables. The change in the means for different efficacy measures between baseline and month 2 was tested using the paired t test. The testing of mean change (difference) in endpoints of interest among different dose groups was performed using ANOVA (analysis of variance). The Tukey HSD method was used for post-hoc pairwise testing. The proportion of patients who achieved their target LDL-C values was calculated and compared between different CVD risk factors groups using the chi-square test. The level of significance was set to P≤.05. AEs were described as frequencies and relative frequencies. The seriousness, intensity and relatedness to study drug were also described. Mean changes in laboratory values were reported.
RESULTS
Of 346 patients screened, 313 completed the study (Figure 1 ). The mean (SD) age of eligible patients was 55 (11.2) years and 48.6% were males (Table 1) . Mean body mass index was 29.2 (4.8) kg/m 2 . Fifty-four patients (17.1%) had CAD, a previous stroke, or peripheral arterial disease (PAD) at baseline and 44.6% of the population had a positive family history of premature CAD. More than half of patients had hypertension and 91 patients (28.8%) had diabetes mellitus; 61.7% of the subjects were smokers, 60.9% were led a sedentary lifestyle, and 46.1% were obese. Based on the SCORE system for CVD risk estimation, almost half of the study subjects were in the very high-risk group and only 6.6% were in the low-risk group. Generic rosuvastatin was administered at a dose of 10 mg/day in 116 patients (36.6%), 20 mg/day in 196 patients (61.8%) and 40 mg/day in 5 patients (1.6%).
By the end of the study (at month 2 after treatment initiation), 1 subject (0.3%) was on a dose of 5 mg/day, 113 subjects (35.6%) were on a dose of 10 mg/day, 199 (62.8%) were on a dose of 20 mg/day and 4 (1.3%) were on a dose of 40 mg/day. LDL-C levels significantly decreased from 4. (Table 2 ) (P<.001).The mean change in LDL-C showed a statistically significant difference between the 3 dose-groups; pairwise post-hoc analysis for mean LDL-C change showed significant differences between the 10 and 20 mg dose groups (P<.001), 10 and 40 mg dose groups (P=.021), but not between the 20 and 40 mg dose groups (P=.425). The mean percent change in LDL-C was -35.0% (21.1%) in the total population. There was a statistically significant difference in the mean percent change in LDL-C level between the three dose groups (P=.039). The mean percent change was highest in subjects receiving rosuvastatin at a dose of 40 mg/day (-47.4%), followed by 20 mg/day (-36.8%), and 10 mg/ day (-31.4%).
At the second month, 260 patients (82.5%) reached their target LDL-C level as set by their physician at baseline (Table 3) . Among these patients, LDL-C levels significantly decreased from 4.3 (0.8) mmol/L (165.9 [32.1] mg/dL) at baseline to 2.6 (0.6) mmol/L (101.8 [24.5] mg/dL) at month 2. Mean change was -1.7 (0.9) mmol/L (-64 [35.5] mg/dL) and percent reduction was 32.6% (22.5%). There was no statistically significant difference in the proportion of patients reaching their target LDL-C level between the three dose groups. Reasons for non-achievement of target LDL-C levels included non-compliance with lifestyle modifications, need for a higher rosuvastatin dose, and primarily the need for a longer treatment period.
Mean TG levels significantly decreased from 2.1 (Table 5) . Only one patient discontinued the drug secondary to headache and insomnia. A statistically significant difference was found in mean AST, ALT, serum creatinine, and serum creatine kinase levels between baseline and month 2 (Table 6 ). However, mean levels remained within the acceptable range. There was no statistically significant difference in the mean change in liver function tests, serum creatinine, and serum creatinine kinase between different dose groups. 
DISCUSSION
Managing patients with dyslipidemia includes lifestyle changes (diet and exercise) as well as drug therapy. In this context, statins are recognized as essential agents for the reduction of CAD risk. Accordingly, this was an observational study assessing the efficacy and safety of a generic formulation of rosuvastatin, in a total of 317 Lebanese hypercholesterolemic patients in routine clinical settings. The study population was heterogeneous and included patients with hypertension (54.4%) and diabetes (28.8%), and patients who were in general at high/very high risk of developing CVD (73.1%).
The mean percent change in LDL-C level was -35% after 2 months of treatment, which is comparable to that reported in other observational studies.
21 Our efficacy results, however, differ from those of some earlier randomized controlled trials (RCTs) using the original rosuvastatin (Crestor). 15, 22, 23 In one study, the reported mean percent change from baseline to week 6 was -50.5%, -57.0%, and -62.6% for the 10-, 20-, and 40-mg dose groups, respectively. This difference can be explained by several factors. Patients in RCTs designed to prove efficacy had higher baseline cholesterol levels (4.1-5.7 mmol/L (160-220 mg/dL)), were healthier (no CVD, diabetes, or obesity), and represented a homogenous group in controlled conditions. 22 Although no studies have been performed on rosuvastatin generics, several studies on other statin generics have found comparable efficacy and safety profiles between generic and innovator statins with short-or long-term use, 24 ,25 even in high-risk populations. 26 One Swedish population-based study even showed that generic statins demonstrated a better level of adherence Table 5 . Description of adverse events. and prescription refill than innovator statins. 27 Another study showed that the increased level of adherence when using generic statins reduced the rate of hospitalization for an acute coronary syndrome or stroke as well as all-cause mortality. 28 On average, 82.5% of our patients achieved their LDL-C target and there was no difference between dose groups in terms of percentage of goal attainment. In the DISCOVERY trial, which compared the efficacy of atorvastatin to that of rosuvastatin, investigators reported that 83.4% of patients on the latter achieved their targets. 29 This high percentage was even reported in studies following patients switching from other statins to rosuvastatin. 30 In our study, generic rosuvastatin reduced TGs by 13.2% and increased HDL-C by 8.2% after 8 weeks of treatment. A systematic review of 108 trials of rosuvastatin reported a 7.3% increase in HDL-C levels with rosuvastatin, which is comparable to our results. This review, however, reported a 19.7-26.7% reduction in TG levels for 10-40 mg/day of rosuvastatin use. This difference can be due to the relatively low baseline TG levels in our study compared to those usually reported in trials. 31 In our study, generic rosuvastatin was well tolerated. The AEs reported during the 8 weeks of therapy were consistent with the literature. Earlier studies on the innovator showed similar AE types but higher AE rates than reported in our study. 22, 29 Although generic rosuvastatin therapy in our study produced a statistically significant elevation in the levels of serum aminotransferases, creatinine, and creatine kinase levels, all changes observed were not clinically significant since mean levels remained within the normal range. This is supported by several trials in which no clinically significant elevation of levels occurred. Even for slight increases, studies suggest that they were only initial changes and no further increases occurred over time. 22, 32 The limitations of the study include its observational nature and lack of a control group, and the relatively short duration of follow-up, which might limit the generalizability of our results. A broader population and longer period of observation might have further supported our results. However, RCTs also have their drawbacks. While several RCTs were done in the early stages before and after approval of rosuvastatin, the generalizability of these RCTs is also limited due to their strict inclusion/exclusion criteria. Thus, there is a need for studies designed like this one to simulate real-life non-research settings.
Rosuvastatin is commonly used in Lebanon. A previous cross-sectional study in Lebanese and Jordanian dyslipidemic patients reported that rosuvastatin was the third most used statin (21.2%) in these populations. 20 The same study, however, reported that LDL-C goals were not achieved in 67.2% of patients with very high cardiovascular risk. It is hoped that with the cost saving of using a generic form of this potent statin, the use of this agent will increase, helping a greater proportion of patients achieve their target LDL-C goals. Although rosuvastatin is generally found to be effective in reducing the LDL-C, the cost of the drug might be of concern to many patients. In Lebanon, Superstat is 33% to 45% less expensive than the innovator drug at available doses. The LDL-C lowering profile of this rosuvastatin generic at a lower cost with no increased risk of AEs will be beneficial and affordable and will reduce health expenses, especially since long-term use is needed for both primary and secondary prevention of CAD. Conducting a cost-effectiveness study might further support this hypothesis.
In conclusion, this observational study showed that a generic rosuvastatin was efficacious and safe in treating hypercholesterolemia for the prevention of CVD in this pool of mostly high-risk Lebanese subjects. The drug showed a favorable safety profile and was able to significantly reduce LDL-C levels and to help in achieving LDL-C target levels in the majority of the patients after only two months of treatment. 
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